Last week, Greg Dombal, President of DLRC’s US office, participated in the inaugural meeting of Accelerator Hub, VITAL – A BARDA BAN Hub! VITAL supports the development and acceleration of next-generation #therapeutic and #vaccine platforms and technologies. Greg delivered an interactive seminar on the regulatory process in the US and strategies for engaging the #FDA to the ten pioneering companies taking part in #VITAL. The companies had specific questions about #INTERACT Meetings, special designations, what questions to ask the FDA and when, and how to bring external #regulatory expertise into their teams. The 90-minute discussion touched on how the FDA works with sponsors and highlighted DLRC's experiences in collaborative work with the agency and its clients. Greg will continue to support VITAL as a strategic regulatory sounding board to help innovators align their regulatory strategies with their business objectives. Are you an anti-infective or anti-viral company ready to bring your therapeutic or vaccine innovations to market? Email us at hello@dlrcgroup.com to discover how DLRC’s strategic expertise can maximise your impact. #RegulatoryAffairs #RegulatoryStrategy #Biotech #Pharma
